PI Industries Limited (PIIND)
Investor Presentation
Investor Presentation - Q2FY27
- Consolidated revenue 17.0bn; EBITDA 2.36bn; PAT 1.22bn
- Domestic revenue grew ~19%; agchem exports declined ~18% due to pricing pressure and genericization
- Biologicals revenue surged 250% globally; health sciences revenue up 20%
- Gross margin impacted by 5% higher input costs and pricing pressure
- Trade working capital reduced by 18 days, releasing 2.98bn cash
- Capex of 5.67bn in H1FY27 for capacity and R&D
- Pipeline includes 20+ products; 5+ new products expected in FY27
- ESG: Featured in S&P Global Sustainability Yearbook 3rd year; top 2 percentile globally
- Strong balance sheet with net cash of 35.7bn
- Focus on innovation, global expansion, and long-term growth
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 PIIND — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add PIIND to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on PI Industries Limited
Important.
The summary above is generated automatically from PI Industries Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.